Lenvatinib/Pembrolizumab Maintained Beneficial Outcomes When

Lenvatinib/pembrolizumab demonstrated efficacy irrespective of tumor burden in advanced renal cell carcinoma in the overall patient population of the phase 3 CLEAR study.

Related Keywords

Germany , United States , America , Lenvatinib Lenvima , University Hospital Essen , Interdisciplinary Genitourinary Oncology , Subgroup Analysis , Western Europe , North America , Immunotherapy In Gu Cancers , News , Genitourinary Cancers , Immuno Oncology ,